Literature DB >> 1903360

On the (near) equivalence of cost-effectiveness and cost-benefit analyses.

C E Phelps1, A I Mushlin.   

Abstract

Many people believe that cost-effectiveness (CE) and cost-benefit (CB) analyses require different assumptions. However, when CE analysis supports decisions to use medical resources, it makes the same assumptions that CB analysis requires. They are mathematically equivalent. Differences between CE and CB hinge more on reporting style than on fundamental assumptions.

Entities:  

Mesh：

Year:  1991        PMID： 1903360     DOI： 10.1017/s0266462300004803

Source DB:  PubMed          Journal:  Int J Technol Assess Health Care        ISSN： 0266-4623            Impact factor:   2.188


  15 in total

Review 1.  Economics notes: types of economic evaluation.

Authors:  S Palmer; S Byford; J Raftery
Journal:  BMJ       Date:  1999-05-15

Review 2.  The (near) equivalence of cost-effectiveness and cost-benefit analyses. Fact or fallacy?

Authors:  C Donaldson
Journal:  Pharmacoeconomics       Date:  1998-04       Impact factor: 4.981

Review 3.  Sample size determination for cost-effectiveness trials.

Authors:  Andrew R Willan
Journal:  Pharmacoeconomics       Date:  2011-11       Impact factor: 4.981

Review 4.  Statistical versus quantitative significance in the socioeconomic evaluation of medicines.

Authors:  B J O'Brien; M F Drummond
Journal:  Pharmacoeconomics       Date:  1994-05       Impact factor: 4.981

5.  Assessing the economic value of a new antidepressant. A willingness-to-pay approach.

Authors:  B J O'Brien; S Novosel; G Torrance; D Streiner
Journal:  Pharmacoeconomics       Date:  1995-07       Impact factor: 4.981

6.  Exploring uncertainty in cost-effectiveness analysis.

Authors:  Karl Claxton
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

7.  Cost-effectiveness analysis and policy choices: investing in health systems.

Authors:  C J Murray; J Kreuser; W Whang
Journal:  Bull World Health Organ       Date:  1994       Impact factor: 9.408

8.  The social value of a QALY: raising the bar or barring the raise?

Authors:  Cam Donaldson; Rachel Baker; Helen Mason; Michael Jones-Lee; Emily Lancsar; John Wildman; Ian Bateman; Graham Loomes; Angela Robinson; Robert Sugden; Jose Luis Pinto Prades; Mandy Ryan; Phil Shackley; Richard Smith
Journal:  BMC Health Serv Res       Date:  2011-01-11       Impact factor: 2.655

9.  Effectiveness and cost-effectiveness of potential responses to future high levels of transmitted HIV drug resistance in antiretroviral drug-naive populations beginning treatment: modelling study and economic analysis.

Authors:  Andrew N Phillips; Valentina Cambiano; Alec Miners; Paul Revill; Deenan Pillay; Jens D Lundgren; Diane Bennett; Elliott Raizes; Fumiyo Nakagawa; Andrea De Luca; Marco Vitoria; Jhoney Barcarolo; Joseph Perriens; Michael R Jordan; Silvia Bertagnolio
Journal:  Lancet HIV       Date:  2014-10-14       Impact factor: 12.767

Review 10.  Welfarism versus extra-welfarism: can the choice of economic evaluation approach impact on the adoption decisions recommended by economic evaluation studies?

Authors:  James Buchanan; Sarah Wordsworth
Journal:  Pharmacoeconomics       Date:  2015-06       Impact factor: 4.981
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.